DisTinGuish Trial: DKN-01 + tislelizumab +/- chemo as 1L/2L GEA. Seems to be a signal in DKK1+ patients (who have an aggressive phenotype). #GI22 abstract 292 @KlempnerSam (@ryanhuey)

#GI22 4⃣/ ✅G/E/GEJ ➡️@KlempnerSam Abs 292 ⏩DisTinGuish Trial ⏩DKN-01➕tisleliz +/- chemo in advanced GEA 🧑‍🏫(DKN-01 is an anti-DKK1 mAb) ⏩49 pts 👉100% ORR in the 12 DKK-1 High patients‼️ (@MPishvaian)

#Myeloma Paper of the Day: Study of circulating cytokines in #myeloma patients finds that specific cytokines besides DKK1 inhibit osteoblastic differentiation of adipocyte-derived MSCs with a skewing towards adipocyte differentiation: https://t.co/oNfWKlnXcl. (@Myeloma_Doc)

looks pretty good DKN-1 + tislelizumab and chemo in gastric/gastroesophageal junction cancer. ORR 68% (90% ORR DKK1-high patients) compared to the standard of care of 47% (@Kevin_W81)

$lptx #dkk1 is an effective and now proven bio marker in solid tumors #esmo21 @LeapTherapeutic @BeiGeneGlobal (@Brownynut)

Dr. Arend presents exciting data of a DKK1 inhibitor (DKN-01) in #endometrialcancer - biomarker selection seems possible using DKK1 expression, WNT mutation or PIK3CA mutation. Will be exciting to see this move forward! #SGOMtg #gyncsm (@ShannonWestin)

Just in @JCOPO_ASCO ,Study by PCF/SU2C team👉Double negative #ProstateCancer (DNPC) with ⬇️AR+ ⬇️neuroendocrine signaling 👉associated with increased Dickkopf-1 (DKK1) expression & immunosuppressed state. https://t.co/msaeJLjNDR Trial with DKKI inhibitor started👇@oncoalert (@neerajaiims)

Dr. Merajver @sofiamerajver discusses role of DKK-1 in dormancy and metastasis @BrownUCancer she uses devices she has built to study complex molecular, cellular and physical factors that regulate metastasis from breast cancer cells into the brain @BrownMedicine @BrownUResearch (@weldeiry)